NCT01520207

Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension

Pilot Study of Intravenous Mannitol During Hemodialysis Initiation to Reduce the Occurrence of Intra-dialytic Hypotension.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Kidney failure can result from a variety of conditions and can be temporary or permanent. Hemodialysis is available as a replacement treatment to perform the work that the kidneys normally do. However, the dialysis procedure can be associated with rapid changes in the composition of the blood - this may lead to changes in blood pressure and in turn reduced blood supply to important parts of the body. We aim to investigate if giving a medicine (called mannitol) during dialysis may be able to reduce the frequency of these low blood pressure events.

Conditions

• Intra-dialytic Hypotension

Interventions

Type	Name	Description
DRUG	Mannitol (20%)	0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
DRUG	0.9% saline	1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment

Timeline

• Start date: 2012-05-01
• Primary completion: 2016-07-01
• Completion: 2018-12-01
• First posted: 2012-01-27
• Last updated: 2019-01-30
• Results posted: 2017-10-19

Locations

1 site across 1 country: United States